Voyager Therapeutics (VYGR) AI Stock Analysis

• Market Cap: $189.70M
• Dividend Yield: N/A
• Average Volume (3M): 763.08K
• Price to Earnings (P/E): 5.0
• Beta (1Y): 1.50
• Revenue Growth: -70.38%
• EPS Growth: -683.06%
• Country: US
• Employees: 172
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 55,468,807
• 10 Day Avg. Volume: 661,352
• 30 Day Avg. Volume: 763,079
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.04
• Enterprise Value/Revenue: 0.17
• Enterprise Value/Gross Profit: 0.17
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $16.38
• Price Target Upside: 378.95% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 10

• Rating: 50 Neutral
• Price Target: $3.50 ▲(2.34% Upside)

Voyager Therapeutics' overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. Technical analysis shows some short-term positive trends, but valuation remains weak due to a negative P/E ratio and no dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Cash Position

With $262 million in cash and a runway extended into 2028, analysts reiterate a Buy rating with key catalysts expected to drive meaningful upside.

Partnerships

The company's gene therapy programs utilize its proprietary TRACER capsid technology, which has shown promise in that it has been the subject of several external partnerships.

Platform Differentiation

Voyager is seen as one of the most differentiated central nervous system platforms in development due to its Alzheimer’s and gene therapy pipeline.

Negative Factors

Clinical Trials Timeline

Partner NBIX remains on track for IND filings for GBA-1 gene therapy for Parkinson/Gaucher and FXN gene therapy by year-end 2025.

Dependency on Milestones

VYGR could receive up to $35 million in milestones from partnered programs entering the clinic.

High Risk

The company has several pipeline products targeting Alzheimer's Disease, which remains an area of high unmet need with high-risk/high-reward characteristics.

Voyager Therapeutics Business Overview & Revenue Model

Company Description

Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company focused on developing innovative treatments for neurological diseases. The company leverages its proprietary adeno-associated virus (AAV) platform to create gene therapies that target conditions such as Parkinson's disease, Huntington's disease, and other disorders of the central nervous system. Voyager’s commitment to advancing gene therapies aims to provide transformative solutions for patients with unmet medical needs in the field of neurology.

How the Company Makes Money

Voyager Therapeutics generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments based on development progress, and royalties on future sales of therapies developed through these collaborations. Additionally, the company may receive funding from government grants or external research organizations to support its research and development efforts. As Voyager progresses its therapeutic candidates through clinical trials, successful outcomes can lead to increased interest from potential partners and investors, further contributing to its revenue streams.

Voyager Therapeutics Financial Statement Overview

Summary

Voyager Therapeutics is facing financial challenges with declining revenues and profitability. The balance sheet shows a stable equity position, but increasing leverage and negative cash flows are concerns. The company needs to address operational inefficiencies to improve financial health.

Income Statement

Voyager Therapeutics has experienced significant revenue volatility, with a notable decline in revenue from 2023 to TTM. The gross profit margin has decreased, and the company is currently operating at a net loss, impacting net profit margins negatively. The EBIT and EBITDA margins are also negative, indicating operational challenges.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, suggesting financial stability. However, the debt-to-equity ratio has increased slightly, indicating a rise in leverage. Return on equity is negative due to net losses, which is a concern for profitability.

Cash Flow

Operating cash flow is negative, reflecting cash burn, but the company has managed to maintain a positive free cash flow growth rate in TTM. The operating cash flow to net income ratio is unfavorable due to negative net income, indicating cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	42.58M	80.00M	250.01M	40.91M	37.41M	171.13M
Gross Profit	42.58M	80.00M	245.57M	34.72M	-36.37M	62.38M
EBITDA	-119.17M	-78.56M	126.45M	-44.65M	-68.45M	31.20M
Net Income	-107.93M	-65.00M	132.33M	-46.41M	-66.03M	36.74M
Balance Sheet
Total Assets	322.10M	393.05M	351.28M	159.36M	193.85M	261.58M
Cash, Cash Equivalents and Short-Term Investments	215.59M	266.68M	230.88M	118.85M	132.54M	181.14M
Total Debt	40.20M	43.73M	20.29M	23.13M	44.18M	47.61M
Total Liabilities	78.16M	93.29M	114.96M	100.34M	98.80M	107.26M
Stockholders Equity	243.94M	299.76M	236.32M	59.02M	95.06M	154.32M
Cash Flow
Free Cash Flow	-115.83M	-18.83M	74.66M	-15.00M	-55.13M	-108.81M
Operating Cash Flow	-113.65M	-15.31M	77.92M	-12.51M	-53.52M	-96.72M
Investing Cash Flow	80.28M	-94.86M	-141.64M	-7.34M	65.91M	113.00M
Financing Cash Flow	1.18M	114.02M	33.65M	1.11M	612.00K	3.16M

Voyager Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Positive. The current price of 3.42 is above the 20-day moving average (MA) of 3.39, above the 50-day MA of 3.27, and below the 200-day MA of 4.21, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 51.23 is Neutral, neither overbought nor oversold. The STOCH value of 18.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VYGR.

Voyager Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FHTX	52 Neutral	$312.61M	―	322.49%	―	-31.30%	36.26%
FDMT	52 Neutral	$304.97M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
VYGR	50 Neutral	$189.70M	5.05	-37.26%	―	-70.38%	-683.06%
TERN	45 Neutral	$634.46M	―	-35.02%	―	―	20.37%
PRME	43 Neutral	$646.85M	―	-154.81%	―	739.42%	24.90%
ANNX	38 Underperform	$236.26M	―	-66.75%	―	―	-5.57%

Voyager Therapeutics Corporate Events

Voyager Therapeutics Approves Stock Plans at Annual Meeting

At the annual meeting held on June 3, 2025, Voyager Therapeutics‘ stockholders approved the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan, both previously adopted by the Board of Directors. Additionally, stockholders elected four Class I directors to serve until the 2028 meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and operational strategies moving forward.